MedPath

Rocuronium

Generic Name
Rocuronium
Drug Type
Small Molecule
Chemical Formula
C32H53N2O4
CAS Number
143558-00-3
Unique Ingredient Identifier
WRE554RFEZ
Background

Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. Sugammadex is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.

Indication

For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Associated Conditions
Muscle fasciculation caused by succinylcholine
Associated Therapies
Curarization therapy, Neuromuscular blocking therapy, Facilitation of small bowel intubation therapy

SPME For Metabolomics And Concomitant Measurements Of Rocuronium Bromide Levels In Liver Transplantation

Completed
Conditions
Liver Failure
Interventions
First Posted Date
2011-07-28
Last Posted Date
2015-04-24
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
28
Registration Number
NCT01404793
Locations
🇨🇦

Toronto General Hospital, Toronto, Ontario, Canada

Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block

Phase 4
Completed
Conditions
Airway Reflexes, Protective
Recovery After Neuromuscular Block
Anesthetic Recovery
Interventions
First Posted Date
2010-09-10
Last Posted Date
2014-05-16
Lead Sponsor
University of California, San Francisco
Target Recruit Count
107
Registration Number
NCT01199237
Locations
🇺🇸

UCSF Moffitt-Long Hospital, San Francisco, California, United States

🇺🇸

UCSF Helen Diller Cancer Center, San Francisco, California, United States

Electromyographic (EMG) on the Anaesthesia Monitor

Phase 4
Completed
Conditions
Anaesthesia
First Posted Date
2010-06-11
Last Posted Date
2010-06-11
Lead Sponsor
Tampere University Hospital
Target Recruit Count
30
Registration Number
NCT01142635
Locations
🇫🇮

Tampere University Hospital, Tampere, Finland

Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 (Study P05977)

Phase 3
Completed
Conditions
Anesthesia
Interventions
First Posted Date
2009-10-02
Last Posted Date
2015-05-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
38
Registration Number
NCT00988520

Study of Efficacy, Pharmacokinetics, and Safety of Bolus Maintenance Doses of Org 9426 (Study P05976)(COMPLETED)

Phase 3
Completed
Conditions
Muscle Relaxation
Interventions
First Posted Date
2009-09-25
Last Posted Date
2015-05-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
40
Registration Number
NCT00984633

The Effect of Rocuronium on the Response of Composite Variability Index (CVI) to Laryngoscopy

Not Applicable
Conditions
Laryngoscopy
Interventions
First Posted Date
2009-06-23
Last Posted Date
2009-06-23
Lead Sponsor
St. Vincent's Medical Center
Target Recruit Count
80
Registration Number
NCT00926718
Locations
🇺🇸

Saint Vincent Catholic Medical Centers, New York, New York, United States

Protocol for Eslax Intravenous Drug Use Investigation (Study P06082)

Completed
Conditions
Anesthesia
Interventions
First Posted Date
2009-05-14
Last Posted Date
2015-10-30
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
3969
Registration Number
NCT00902070

Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)

Phase 3
Completed
Conditions
Neuromuscular Blockade
Interventions
First Posted Date
2008-09-11
Last Posted Date
2015-06-30
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
161
Registration Number
NCT00751179

Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)

Phase 3
Completed
Conditions
Anesthesia, General
Interventions
First Posted Date
2008-07-30
Last Posted Date
2017-05-16
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
140
Registration Number
NCT00724932
© Copyright 2025. All Rights Reserved by MedPath